secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001104659-23-116047
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elutia closes Orthobiologics divestiture for up to $35M in cash proceeds
------------------------------------------------------------------------

- Upfront payment of $15M due Nov 17, 2023, plus up to $20M earnout over 5 years.
- Combined with Sept 2023 private placement, total potential cash exceeds $60M.
- Company refocuses on drug-eluting biomatrix platform, including CanGaroo RM.
- Transaction closed Nov 8; buyer is Berkeley Biologics (GNI Group subsidiary).
- Mizuho Securities acted as financial advisor; Kilpatrick Townsend as legal advisor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465923116047/0001104659-23-116047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465923116047/tm2330025d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-116047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer